Company / Operating Income
Kiniksa Pharmaceuticals International, plc Operating Income History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$77.2M
FY2025
5-year range
-$170.0M / $77.2M
FY2021-FY2025
Trend
+269.3%
vs FY2024
Sector context
#41 of 204
Health Care
What the data says
Operating Income changed +269% YoY in FY2025, a notable deviation from the 8-year average annual change of -23%.
Based on SEC 10-K filings.
$77M in FY2025 with a 3-year CAGR of +99.2%. Top quartile in the Health Care sector.
Improved from -$25M to $77M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- +99.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 20% in Health CareTop 20% of 204This company $77.2M Sector average $107.8M
▼
-28.3% below sector average
Key checks
Key Insights
- 3-year CAGR of +99.2%, indicating consistent growth.
- In FY2025, operating income increased 269.3% year-over-year.
- Ranks #41 out of 204 companies in the Health Care sector.
- Lowest operating income in the period was in FY2021.
Company context
Key Data Points
- Negative profit margin: -10.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $77.2M | +269.3% |
| FY2024 | -$45.6M | -81.0% |
| FY2023 | -$25.2M | -357.8% |
| FY2022 | $9.8M | +105.8% |
| FY2021 | -$170.0M | -8.0% |
| FY2020 | -$157.4M | +7.4% |
| FY2019 | -$170.0M | -57.1% |
| FY2018 | -$108.2M | -65.4% |
| FY2017 | -$65.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026